Biosimilars

Why biosimilars are an opportunity, but could also be a trap.

The biosimilar market is expected to grow between 22% and 30% annually in Europe within the coming years. The main driver of this growth...

The Second Wave of Biosimilars. How to find the best ones?

A few days ago, Biopharmalinks (Emergpharma, www.emergpharmalinks.com) finished the first part of its ambitious research on biosimilars...

13 recommendations to succeed when selecting 2nd wave biosimilars.

Risks associated with the decision to develop biosimilars As we have seen in recent years, many companies that have developed or...

Tenders and long term sustainability of biosimilars in Europe

As we insist on almost all our articles, biosimilars are not an option, but a need. As commented in our presentation last Thursday at...

Biosimilars to increase adoption of biologics in Emerging Markets. Past Evidence for the Future.

In previous articles, I have shown some ideas about the past, present, and future of biosimilars. Once again, I would like to insist on...

At least 255 pharmaceuticals playing biosimilars. Rise of the "Pharmerging" middle class.

Preliminary results of the Emergpharma’s “biosimilar 255 tracking January 2020” Emergpharma has just completed the first phase of its...

Is it true that biosimilars will increase the use of the molecule? Not always...

Conclusions of a survey on biosimilar adoption in the EU Top 5 A few weeks ago I published an article in Biosimilar Development on the...

Commercial strategies for biosimilars: Any sense to register several brands?

Biosimilars have traditionally been seen by large pharmaceutical companies as a threat to their most profitable products and the priority...

Anti TNF biosimilars infliximab and etanercept conquer 63% and 44% of the Top 5 EU in under 3 years.

The available data on biosimilars in Europe are still insufficient to carry out a rigorous analysis to show correlations. However, given...

Biosimilars following same pattern as generics? Neupogen keeps just 6% of EU market after 10 years.

Twelve years after the launch of the first biosimilar in Europe, there are still limited data available on the medium-term impact of the...

Biosimilars of Rituximab grab 50% market share in top EU markets after less than 2 years.

Mabthera (rituximab) has faced the launch of first biosimilars in EU markets between 2016 and 2018. Some outcomes from Emergpharma's...

Notes on the German generics and biosimilars market 2016-2018.

German generics market is the biggest in Europe in terms of values and units. It is also one of the most dynamic and with the largest...

Follow us on: